Stay updated on Dose Ranging Study of GSK1265744 Plus NRTIs in HIV-1 Clinical Trial
Sign up to get notified when there's something new on the Dose Ranging Study of GSK1265744 Plus NRTIs in HIV-1 Clinical Trial page.

Latest updates to the Dose Ranging Study of GSK1265744 Plus NRTIs in HIV-1 Clinical Trial page
- Check5 days agoChange DetectedThe web page has been updated to include new drug information related to HIV treatment, specifically mentioning Efavirenz and Rilpivirine, while removing extensive details about the study design and phases. The revision number has also been updated.SummaryDifference8%
- Check13 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check20 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check27 days agoNo Change Detected
- Check56 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.5%
- Check71 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.5%
- Check78 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.0%
Stay in the know with updates to Dose Ranging Study of GSK1265744 Plus NRTIs in HIV-1 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dose Ranging Study of GSK1265744 Plus NRTIs in HIV-1 Clinical Trial page.